Prospects for the therapy and prevention of dengue virus infections (Q35941645)

11 August 2017

1 reference

title

Prospects for the therapy and prevention of dengue virus infections (English)

1 reference

11 August 2017

0 references

Elsa B Damonte

1

1 reference

PubMed ID

15530563

11 August 2017

Carlos A Pujol

series ordinal

2

1 reference

PubMed ID

15530563

11 August 2017

Celia E Coto

series ordinal

3

1 reference

11 August 2017

1 January 2004

1 reference

Advances in Virus Research

11 August 2017

1 reference

11 August 2017

63

1 reference

11 August 2017

239-285

1 reference

Study of biologic attributes of Cuban dengue 2 virus after serial passage in primary dog kidney cells

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Development of a novel mouse model for dengue virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Correlation of E protein binding with cell susceptibility to dengue 4 virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Recent advances in vaccines against viral haemorrhagic fevers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Current status of flavivirus vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxi

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Live attenuated tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Pathogenesis of dengue virus diseases: missing pieces in the jigsaw

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Analysis of antibody-independent binding of dengue viruses and dengue virus envelope protein to human myelomonocytic cells and B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Synergistic In Vitro Interactions between Alpha Interferon and Ribavirin against Bovine Viral Diarrhea Virus and Yellow Fever Virus as Surrogate Models of Hepatitis C Virus Replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Growth-restricted dengue virus mutants containing deletions in the 5' noncoding region of the RNA genome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue vaccine design: issues and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Flavivirus genome organization, expression, and replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Production of the baculovirus-expressed dengue virus glycoprotein NS1 can be improved dramatically with optimised regimes for fed-batch cultures and the addition of the insect moulting hormone, 20-Hydroxyecdysone

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Demonstration of binding of dengue virus envelope protein to target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Questions on viral population biology to complete dengue puzzle

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Blocking the dengue virus 2 infections on BHK-21 cells with purified recombinant dengue virus 2 E protein expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

RNA virus error catastrophe: direct molecular test by using ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Recombinant dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Sulfated seaweed polysaccharides as antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Rates of spontaneous mutation among RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Virucidal activity of essential oils from aromatic plants of San Luis, Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Biochemistry and clinical applications of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The broad spectrum antiviral agent ribavirin inhibits capping of mRNA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Pathogenesis of dengue: challenges to molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The future of dengue vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The machinery for flavivirus fusion with host cell membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

1 reference

7 January 2021

Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The causes and consequences of genetic variation in dengue virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Analysis of the steps involved in Dengue virus entry into host cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Early clinical and laboratory indicators of acute dengue illness

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Development of new vaccines against dengue fever and Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Inhibition of dengue virus replication by amantadine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Suppression of dengue virus replication in vitro by rimantadine hydrochloride.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Antiviral effects if ribavirin and 6-mercapto-9-tetrahydro-2-furylpurine against dengue viruses in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

In vitro antiviral activity on dengue virus of marine natural products.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Perspectives for the treatment of infections with Flaviviridae

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A novel model for the study of the therapy of flavivirus infections using the Modoc virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Salicylates inhibit flavivirus replication independently of blocking nuclear factor kappa B activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A different mode of entry by dengue-2 neutralisation escape mutant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Heparin inhibits dengue-2 virus infection of five human liver cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue 1 virus binding to human hepatoma HepG2 and simian Vero cell surfaces differs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Lassa fever. Effective therapy with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

α-Glucosidase inhibitors as potential broad based anti-viral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A ligand-binding pocket in the dengue virus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Non Fc receptor-mediated infection of human macrophages by dengue virus serotype 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Antibody-dependent enhancement of infection and the pathogenesis of viral disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Identification of active antiviral compounds against a New York isolate of West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Processing of the dengue virus type 2 proteins prM and C-prM.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Vaccines for the prevention of neglected diseases--dengue fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Inhibitory potential of neem (Azadirachta indica Juss) leaves on dengue virus type-2 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Expression of the NS1 gene of dengue virus type 2 using vaccinia virus. Dimerisation of the NS1 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Immunization with DNA through the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Traditional and novel approaches to flavivirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Novel DL-galactan hybrids from the red seaweed Gymnogongrus torulosus are potent inhibitors of herpes simplex virus and dengue virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Immunoreactivity and protective effects in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Molecular evolution and distribution of dengue viruses type 1 and 2 in nature

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Molecular evolution of dengue type 2 virus in Thailand.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Immunopathogenesis of Dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Three classes of cell surface receptors for alphaherpesvirus entry

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Heparan sulfate: anchor for viral intruders?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Molecular Breeding of Genes, Pathways and Genomes by Dna Shuffling.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Effect of a Nuclease-Resistant Derivative of PolyriboinosinicPolyribocytidylic Acid Complex on Yellow Fever in Rhesus Monkeys (Macaca mulatta)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Flaviviruses can mediate fusion from without in Aedes albopictus mosquito cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mechanisms of action of ribavirin in antiviral therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Protection Against Japanese Encephalitis Virus in Mice and Hamsters by Treatment with Carboxymethylacridanone, a Potent Interferon Inducer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Characterisation of inter- and intra-molecular interactions of the dengue virus RNA dependent RNA polymerase as potential drug targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Towards a new generation of flavivirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Hepatitis C virus therapies: current treatments, targets and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Immunology: What is the proximal cause of inflammation?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue Type 3 Virus in Plasma Is a Population of Closely Related Genomes: Quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Widespread intra-serotype recombination in natural populations of dengue virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Antiviral effects of an iminosugar derivative on flavivirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Respiratory syncytial virus (RSV) disease and prospects for its control

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Evidence that flavivirus NS1-NS2A cleavage is mediated by a membrane-bound host protease in the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Impact of dengue/dengue hemorrhagic fever on the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

New mouse model for dengue virus vaccine testing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Dengue virus structural differences that correlate with pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Inhibition of dengue virus by novel, modified antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Mutagenesis of the NS3 protease of dengue virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

Identification of specific nucleotide sequences within the conserved 3'-SL in the dengue type 2 virus genome required for replication

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3527%2804%2963004-1

7 January 2021

10.1016/S0065-3527(04)63004-1

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15530563